longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Abpro Holdings, Inc.

ABPO

----
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 0.57, above the reasonable range, cheaper than 11.72% of the time in the past 1 years, and the industry ranks 7/601, the industry Median -2.50.

0.569xP/E
$0.19Stock price
$0.34Earnings per share
0.569xP/E
Stock price$0.19Earnings per share$0.34

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-0.40x
Typical range
-37.37x–-0.01x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GRFSUSGRIFOLS SA
9.89x42.44%$5.19B
ACADUSAcadia Pharma
12.60x73.68%$4.80B
PURRUSHyperliquid Strategies
8.97x93.15%$2.30B
AUPHUSAurinia Pharma
6.82x54.40%$2.14B
ADMAUSAdma Biologics
12.24x35.42%$2.07B
LKFTUSLakefront Biotherapeutics
2.52x115.23%$1.74B
VORUSVor BioPharma
2.10x89.77%$1.32B
ABUSUSArbutus Pharma
6.59x533.09%$1.01B
RIGLUSRigel Pharma
2.74x83.91%$882.44M
BVNRYUSBavarian Nordic A/S
3.32x--$795.30M
IRWDUSIronwood Pharma
5.19x715.55%$674.18M
QTTBUSQ32 Bio
9.78x161.36%$330.44M
AGENUSAgenus
3.40x--$312.44M
CUVLUSClinuvel Pharmaceuticals
13.09x--$300.05M
CGENUSCompugen
6.65x173.68%$233.97M
PLXUSProtalix Biotherap
11.23x400.00%$212.71M
VXRTUSVaxart
3.05x328.57%$117.78M
RLYBUSRallybio
1.97x131.45%$89.61M
FBIOUSFortress Biotech
0.81x3,742.86%$84.04M
SPROUSSpero Therap
8.91x293.33%$65.81M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.